Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin™)

Breast Cancer Research and Treatment

Volumn 82, Issue 1, 2003, Pages 23-28

  Fuchs, Ilka B ^a   Landt, Solveig ^a   Bueler, Helmut ^b   Kuehl, Uwe ^a   Coupland, Sarah ^a   Kleine Tebbe, Anke ^a   Lichtenegger, Werner ^a   Schaller, Gerhard ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cardiac dysfunction; Cardiotoxicity; HER2; HER4; Myocardium; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER 4 PROTEIN; PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CARDIOTOXICITY; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; DRUG EXPOSURE; FLUORESCENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HEART DISEASE; HEART INJURY; HEART MUSCLE; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN ANALYSIS; STAINING;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEART DISEASES; HUMANS; IMMUNOHISTOCHEMISTRY; MYOCARDIUM; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 0345688767     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000003916.39959.73     Document Type: Article

References (22)

1. Baseiga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26: 78-83, 1999
2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2638, 1999
3. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001
5. Feldman AM, Lorell BH, Reis SE: Trastuzumab in the treatment of metastatic breast cancer. Anticancer therapy versus cardiotoxicity. Circulation 102: 272-274, 2000
6. Ewer MS, Gibbs HR, Swafford J, Benjamin RS: Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26: 96-101, 1999
7. Cook-Bruns N: Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61: 58-66, 2001
8. Aikat S, Francis GS: Trastuzumab therapy and the heart: palliation at what cost? Congest Heart Fail 7: 188-190, 2001
9. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378: 394-398, 1995
10. Chien KR: Stress pathways and heart failure. Cell 98: 555-558, 1999
11. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA: Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273: 10261-10269, 1998
12. Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP: Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology 139:4756-764, 1998
13. Rohrbach S, Yan X, Weinberg EO, Hasan F, Bartunek J, Marchionni MA, Lorell BH: Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation 100: 407-412, 1999
14. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ: Expression of the c-erbB-4/HER 4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 185: 236-245, 1998
15. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC: Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66: 1116-1121, 1992
16. Marchionni MA: Cell-cell signaling, neu tack on neuregulin. Nature 378: 334-335, 1995
17. Chien KR: Myocyte survival pathways and cardiomyopathy: implications for trastuzumab toxicity. Semin Oncol 27: 9-14, 2000
18. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross Jr J, Chien KR, Lee KF: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med 8: 459-465, 2002
19. Qiu Y, Ravi L, Kung HJ: Requirement of ErbB2 for signaling by interleukin-6 in prostate carcinoma cells Nature 393: 83-85, 1998
20. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross Jr J, Muller W, Chien KR: Loss of gp 130 cardiac muscle cell survival pathway is a critical event in the onset of muscle cell survival during biomechanical stress. Cell 97: 189-198, 1999
21. Uray IP, Connelly JH, Thomazy V, Shipley GL, Vaughn WK, Frazier OH, Taegtmeyer H, Davies PJ: Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transplant 21: 771-782, 2002
22. Schneider JW, Chang AY, Rocco TP: Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol 28: 8-26, 2001